Team News Riveting
Hyderabad May 24
Everest Organics Limited today announced the successful development of an anti-fungal active pharmaceutical ingredient (API) “Posaconazole” meant to treat black fungus patients.
The drug was developed at the lab scale in the existing Research and Development (R&D) facility of Everest Organics Limited. Posaconazoleis a triazole antifungal agent indicated for treating mucormycosis patients popularly known as Black Fungus in post COVID complications.
“The Everest Organics Limited has successfully developed the API Posaconazole using its own in-house R&D strength at lab scale in a short span of time. Further we are in an advanced stage of commercializing the same,” Dr Srikakarlapudi Sirisha, Director of Everest Organics said.
Everest has successfully in the near past launched and commercialized ‘Oseltamivir’ and ‘Remdesivir’ both being used for COVID-19. “Now we are more confident and are poised for development of more niche products in the quickest span of time because of our R&D strength,” Dr Sirisha added.
Everest Organics Limited is a fast growing API and Bulk drug manufacturing company with world class facilities and is committed to manufacturing excellent quality products and customer service. The Company produces Active Pharma Intermediates “APls” for quality conscious customers around the globe. Everest Organics Limited supports customers with unique value, niche products range and research driven approach.
The USFDA approved API facility in Hyderabad manufactures and exports various APls products to more than 40 countries as well as caters to local demand in the market in India.
